Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials.

ABSTRACT:

Introduction

Tobacco use can adversely affect cancer treatment outcomes, yet routine assessment has not been fully incorporated into oncology clinical trials. In 2012, rates of tobacco use assessment in actively accruing National Cancer Institute (NCI) trials were < 30% at enrollment and < 5% during follow-up, prompting efforts by the NCI and major oncology associations to promote and standardize tobacco assessment in oncology research and practice (including development of the Cancer Patient Tobacco Use Questionnaire [C-TUQ]). This study was conducted to re-examine assessment patterns in 2022 (including utilization of the C-TUQ) and evaluate progress.

Aims and methods

Protocols and forms from 144 actively accruing (as of December 2022) NCI National Clinical Trials Network (

SUBMITTER: Price SN 

PROVIDER: S-EPMC12453689 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature